Standout Papers

Cabozantinib (XL184), a N... 2011 2026 2016 2021 2011 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
    2011 1.0k citations F. Michael Yakes, Jason Chen et al. Molecular Cancer Therapeutics profile →

Immediate Impact

3 by Nobel laureates 5 from Science/Nature 61 hit
Sub-graph 1 of 21

Citing Papers

Renal cell carcinoma
2024 Hit
Thyroid cancer
2023 Hit
10 intermediate papers

Works of Yu-Chien Chou being referenced

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
2011 Hit

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Yu-Chien Chou 479 442 413 241 199 5 1.1k
Yongchang Shi 533 1.1× 575 1.3× 442 1.1× 260 1.1× 209 1.1× 9 1.3k
Jessica Orf 505 1.1× 542 1.2× 432 1.0× 243 1.0× 202 1.0× 9 1.2k
Scott R. McDonnell 622 1.3× 684 1.5× 621 1.5× 200 0.8× 210 1.1× 13 1.3k
Jingrong Jean Cui 529 1.1× 722 1.6× 449 1.1× 454 1.9× 151 0.8× 16 1.3k
Erina Hatashita 579 1.2× 588 1.3× 492 1.2× 98 0.4× 130 0.7× 17 1.0k
Gunnar Schütz 527 1.1× 353 0.8× 332 0.8× 300 1.2× 150 0.8× 15 1.2k
J. Rafael Sierra 363 0.8× 580 1.3× 248 0.6× 221 0.9× 131 0.7× 18 1.1k
Shawna Organ 302 0.6× 513 1.2× 223 0.5× 243 1.0× 179 0.9× 9 968
Linda M. Murphy 334 0.7× 685 1.5× 251 0.6× 122 0.5× 200 1.0× 14 1.1k
Gareth Hughes 625 1.3× 688 1.6× 321 0.8× 60 0.2× 266 1.3× 22 1.3k

All Works

Loading papers...

Rankless by CCL
2026